Prosecution Insights
Prosecution Insights
Technology area: Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Nightingale Health Oyj is managing 2 pending office actions in the Chemistry & Materials technology area. These actions are split between 2 distinct examiners and 2 distinct art units. This indicates that each pending matter is being handled by a different individual in a different technical group. The use of 2 distinct art units suggests that the company's technology spans different specialized classifications within the office. Prosecution strategy must account for the distinct requirements of these 2 separate examiners and their respective art units within the Chemistry & Materials sector.
GZYBOWSKI, MICHAEL STANLEY is the busiest examiner, with 1 pending office action. Since there are 2 pending office actions in total and 2 distinct examiners, each examiner is responsible for 1 case. This distribution means that no single examiner dominates the company's current prosecution landscape. Practitioners should develop tailored approaches for both distinct examiners to ensure consistent progress across the portfolio. The outcome of each action is independent, given the involvement of 2 distinct art units and 2 distinct examiners.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GZYBOWSKI, MICHAEL STANLEY | 1 | 68.3% | +52.0% |
| FRITCHMAN, REBECCA M | 1 | 45.7% | +35.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18277838 | USE OF GLYCOPROTEIN ACETYLS FOR DETERMINING THE RISK OF DEVELOPING ATRIAL FIBRILLATION AND/OR FLUTTER | GZYBOWSKI, MICHAEL STANLEY | 9d overdue |
| 18011082 | METHOD FOR DETERMINING WHETHER A SUBJECT HAS A DISEASE OR CONDITION OR IS AT RISK OF DEVELOPING A DISEASE OR CONDITION | FRITCHMAN, REBECCA M | 9d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18277838 | USE OF GLYCOPROTEIN ACETYLS FOR DETERMINING THE RISK OF DEVELOPING ATRIAL FIBRILLATION AND/OR FLUTTER | GZYBOWSKI, MICHAEL STANLEY | 9d overdue |
| 18011082 | METHOD FOR DETERMINING WHETHER A SUBJECT HAS A DISEASE OR CONDITION OR IS AT RISK OF DEVELOPING A DISEASE OR CONDITION | FRITCHMAN, REBECCA M | 9d overdue |
| Art Unit | Apps |
|---|---|
| 1798 | 1 |
| 1758 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18277838 | USE OF GLYCOPROTEIN ACETYLS FOR DETERMINING THE RISK OF DEVELOPING ATRIAL FIBRILLATION AND/OR FLUTTER | GZYBOWSKI, MICHAEL STANLEY | 1798 | §101§103 | Final Rejection | 9d overdue | Pending | Aug 18, 2023 |
| 18011082 | METHOD FOR DETERMINING WHETHER A SUBJECT HAS A DISEASE OR CONDITION OR IS AT RISK OF DEVELOPING A DISEASE OR CONDITION | FRITCHMAN, REBECCA M | 1758 | §103§112 | Non-Final OA | 9d overdue | Pending | Dec 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial